Inclusion Body Myositis

Keywords: inclusion body myositis; sporadic inclusion body myositis (sIBM) - common myopathy in Caucasians over 50 years of age; epidemiology and genetic susceptibility; genetic susceptibility, linked to HLA-DR3 and 8.1 MHC ancestral haplotype (AH) in West Australian cohort; serum CK level - normal or mildly elevated (up to 10 times normal); no therapy currently - for stopping disease progression; intravenous immunoglobulin therapy (IVIG) - short-term benefit in selected cases; glucocorticoids and cytotoxic agents